Key statistics
52-week range
Short selling activityProvided by S&P Global Market Intelligence
Open | 1.04 |
---|---|
High | 1.09 |
Low | 1.04 |
Bid | 1.06 |
Offer | 1.08 |
Previous close | 1.05 |
Average volume | 1.86m |
---|---|
Shares outstanding | 34.90m |
Free float | 34.26m |
P/E (TTM) | -- |
Market cap | 36.65m USD |
EPS (TTM) | -2.78 USD |
Data delayed at least 15 minutes, as of Nov 22 2024 16:28 GMT.
More ▼
- RAPT Therapeutics Reports Third Quarter 2024 Financial Results
- Based on Recent FDA Feedback RAPT Therapeutics Stops Zelnecirnon Program Following Clinical Hold Due to Single SAE of Severe Liver Injury
- RAPT Therapeutics Reports Second Quarter 2024 Financial Results
- RAPT Therapeutics Reports First Quarter 2024 Financial Results
- RAPT Therapeutics Announces Promising Results from Phase 2 Trial of Tivumecirnon in Combination with Anti-PD-1 Immunotherapy in CPI-Experienced Head and Neck Cancer Patients
- RAPT Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results
- RAPT Therapeutics Announces Multiple Late-Breaking Presentations at the Upcoming American Association for Cancer Research (AACR) Annual Meeting
- RAPT Therapeutics Announces Clinical Hold on Studies Evaluating Zelnecirnon
- RAPT Therapeutics Bolsters Leadership Team with the Appointment of Nipun Davar, Ph.D., as Senior Vice President of Technical Operations
- RAPT Therapeutics to Participate in the Guggenheim Healthcare Talks 6th Annual Biotechnology Conference
More ▼